We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Gamida Cell Ltd
2 own
11 watching
Current Price
$2.37
$0.21
(9.72%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
176.76M
52-Week High
3.66
52-Week Low
0.56
Average Volume
3.39M
Dividend Yield
--
P/E Ratio
--
Market Capitalization176.76M52-Week High3.6652-Week Low0.56Average Volume3.39MDividend Yield--P/E Ratio--What does the Gamida Cell Ltd do?
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company s lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Read More
News & Events about Gamida Cell Ltd.
PR Newswire
1month ago
Thinking about buying stock in CNS Pharmaceuticals, Dermata Therapeutics, XPO, Gamida Cell, or Kingsoft Cloud? Thinking about buying stock in CNS Pharmaceuticals, Dermata Therapeutics, XPO, Gamida Cell, or Kingsoft Cloud? PR Newswire NEW YORK, April 20, 2023 NEW YORK, April 20, 2023 /PRNewswire...
Business Wire
3 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that two oral presentations and a poster presentation highlighting Gamida Cells investigational product candidates, omidubicel and GDA-201, were shared at the 2023 Tandem...
Ticker Report
6 months ago
Gamida Cell (NASDAQ:GMDA Get Rating) had its price objective cut by equities researchers at Needham Company LLC from $9.00 to $8.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. Needham &#...
Business Wire
6 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: 34th Annual Piper...
Business Wire
7 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced encouraging preclinical data on GDA-501, a genetically modified NAM (nicotinamide) Natural Killer (NK...
Frequently Asked Questions
Frequently Asked Questions
What is Gamida Cell Ltd share price today?
Can Indians buy Gamida Cell Ltd shares?
How can I buy Gamida Cell Ltd shares from India?
Can Fractional shares of Gamida Cell Ltd be purchased?
What are the documents required to start investing in Gamida Cell Ltd stocks?
What is today’s traded volume of Gamida Cell Ltd?
What is today’s market capitalisation of Gamida Cell Ltd?
What is the 52-Week High and Low Range of Gamida Cell Ltd?
What percentage is Gamida Cell Ltd down from its 52-Week High?
What percentage is Gamida Cell Ltd up from its 52-Week Low?
Current Price
$2.37
$0.21
(9.72%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.